<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098823</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-002</org_study_id>
    <nct_id>NCT03098823</nct_id>
  </id_info>
  <brief_title>A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE</brief_title>
  <acronym>RIFLE</acronym>
  <official_title>A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampel BioSolutions, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampel BioSolutions, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as&#xD;
      measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 months</time_frame>
    <description>Fatigue as measured in FACIT-F by patient</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Lupus Erythematosus</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>RAYOS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IR prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAYOS</intervention_name>
    <description>FDA approved RAYOS for indication of fatigue in Lupus.</description>
    <arm_group_label>RAYOS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>FDA approved corticosteroid frequently used for SLE.</description>
    <arm_group_label>IR prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent agreeing to all study procedures, before any&#xD;
             study-specific procedures are done.&#xD;
&#xD;
          2. Males or non-pregnant females, aged 18 years or older&#xD;
&#xD;
          3. Diagnosis of SLE by either the American College of Rheumatology (ACR) or Systemic&#xD;
             Lupus International Collaborating Clinics Classification (SLICC) criteria&#xD;
&#xD;
          4. Fatigue measured by FACIT-F ≤30.&#xD;
&#xD;
          5. On a stable regimen of IR prednisone (5 to 15 mg/day) for a period of at least 30 days&#xD;
             prior to Screening, expected to remain stable for the next 6 months.&#xD;
&#xD;
          6. On a stable SLE treatment regimen for a period of at least 30 days prior to Screening,&#xD;
             and expected to remain stable for the next 6 months. Any of the following medications&#xD;
             are permitted if stable for at least 30 days prior to Screening and expected to remain&#xD;
             stable for the next 6 months:&#xD;
&#xD;
               -  Hydroxychloroquine or equivalent anti-malarial&#xD;
&#xD;
               -  Other immunosuppressive or immunomodulatory agents including methotrexate,&#xD;
                  azathioprine, leflunomide, mycophenolate (including mycophenolate sodium or&#xD;
                  mycophenylate mofetil at no more than 2 grams/day), belimumab, cyclophosphamide,&#xD;
                  calcineurin inhibitors (e.g. tacrolimus, cyclosporine)&#xD;
&#xD;
          7. Entry of daily ePRO data on 11 of 14 days during the baseline period, and completion&#xD;
             of at least 6 out of the 8 weekly ePRO questionnaires during the baseline period&#xD;
&#xD;
          8. Willing and able to perform and comply with all study procedures, including taking&#xD;
             pills daily as prescribed, completing the ePROs on the smart phone, wearing the smart&#xD;
             watch day and night, bringing the smartphone on all activities away from home (e.g.,&#xD;
             walks, errands, visiting, shopping, traveling), keeping the smartphone and smartwatch&#xD;
             charged daily, carefully using the smartphone and smartwatch as clinical tools and&#xD;
             keeping them secure from others, and attending monthly clinic visits as scheduled&#xD;
&#xD;
          9. Females of childbearing potential must be currently using a highly effective method of&#xD;
             contraception that may include, but is not limited to, abstinence, sex only with&#xD;
             persons of the same sex, monogamous relationship with vasectomized partner,&#xD;
             hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine&#xD;
             device, or use of a spermicide combined with a barrier method (e.g., condom,&#xD;
             diaphragm) for 30 days before and 90 days after receiving the study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously taken any of the following medications:&#xD;
&#xD;
               -  RAYOS®&#xD;
&#xD;
               -  Rituximab within 6 months prior to Screening&#xD;
&#xD;
               -  Any investigational therapy within 3 months or 5 half-lives of the agent prior to&#xD;
                  Screening&#xD;
&#xD;
          2. History of noncompliance with taking pills as prescribed.&#xD;
&#xD;
          3. Rapidly progressive neurologic disease&#xD;
&#xD;
          4. Rapidly progressive renal disease (defined by proteinuria &gt;6 g/24 hours or equivalent&#xD;
             using spot urine protein to creatinine ratio, or serum creatinine &gt;2.5 mg/dL)&#xD;
&#xD;
          5. Diagnosis of fibromyalgia&#xD;
&#xD;
          6. Any of the following clinical laboratory abnormalities:&#xD;
&#xD;
               -  Hemoglobin &lt;8.0 mg/dL&#xD;
&#xD;
               -  Platelet count &lt;50,000/mm3&#xD;
&#xD;
               -  White blood count (WBC) ≤ 2000/mm3; may be 1999-1000/mm3 if stable and related to&#xD;
                  SLE&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≤1000/mm3; may be 500-999/mm3 if stable and&#xD;
                  related to SLE&#xD;
&#xD;
               -  Aspartate transaminase (AST) or alanine transaminase (ALT) ≥3× upper limit of&#xD;
                  normal (ULN) unless related to SLE&#xD;
&#xD;
               -  Calculated creatinine clearance ≤25 mL/min per 1.73 m2 (by Cockcroft-Gault&#xD;
                  equation)&#xD;
&#xD;
          7. Grade 3 or greater laboratory abnormality based on the National Cancer Institute&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE; Appendix 3) except for the&#xD;
             following that are allowed:&#xD;
&#xD;
               -  Activated partial thromboplastin time (PTT) &gt; &gt;2.5× ULN due to lupus&#xD;
                  anticoagulant and not related to liver disease or anti-coagulant therapy&#xD;
&#xD;
               -  Hypoalbuminemia &lt;2 g/dL due to chronic lupus nephritis, and not related to liver&#xD;
                  disease&#xD;
&#xD;
               -  Gamma glutamyl transferase (GGT) &lt;20× ULN due to lupus hepatitis, and not related&#xD;
                  to alcoholic liver disease, uncontrolled diabetes, or viral hepatitis. If&#xD;
                  present, any abnormalities in the ALT and/or AST must be ≤5× ULN&#xD;
&#xD;
          8. Pregnant or nursing, or females not using effective contraception&#xD;
&#xD;
          9. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or&#xD;
             dependence within 1 year prior to Screening&#xD;
&#xD;
         10. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             not caused by SLE (e.g., diabetes, cardiovascular, pulmonary, hematologic,&#xD;
             gastrointestinal, neurological, or infectious) which, in the opinion of the&#xD;
             Investigator, could confound the results of the study or put the subject at undue risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller School of Medicine at the University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center-Memorial Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The MetroHealth System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 14, 2021</submitted>
    <returned>November 10, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

